Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Immucell (ICCC) Other Non-Current Liabilities (2016 - 2023)

Historic Other Non-Current Liabilities for Immucell (ICCC) over the last 9 years, with Q2 2023 value amounting to $9.3 million.

Immucell's Other Non-Current Liabilities changed N/A to $9.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $9.3 million, marking a year-over-year change of. This contributed to the annual value of $58526.0 for FY2019, which is N/A changed from last year.
Immucell's Other Non-Current Liabilities amounted to $9.3 million in Q2 2023.
Over the past 5 years, Immucell's Other Non-Current Liabilities peaked at $9.6 million during Q1 2023, and registered a low of $57216.0 during Q2 2019.